HSIC vs. CAH, PDCO, OMI, MCK, COR, GEHC, BIIB, RMD, ICLR, and BNTX
Should you be buying Henry Schein stock or one of its competitors? The main competitors of Henry Schein include Cardinal Health (CAH), Patterson Companies (PDCO), Owens & Minor (OMI), McKesson (MCK), Cencora (COR), GE HealthCare Technologies (GEHC), Biogen (BIIB), ResMed (RMD), ICON Public (ICLR), and BioNTech (BNTX). These companies are all part of the "medical" sector.
Henry Schein (NASDAQ:HSIC) and Cardinal Health (NYSE:CAH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Henry Schein has a net margin of 3.12% compared to Cardinal Health's net margin of 0.25%. Henry Schein's return on equity of 13.51% beat Cardinal Health's return on equity.
Cardinal Health received 530 more outperform votes than Henry Schein when rated by MarketBeat users. Likewise, 71.70% of users gave Cardinal Health an outperform vote while only 51.54% of users gave Henry Schein an outperform vote.
Henry Schein has higher earnings, but lower revenue than Cardinal Health. Henry Schein is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.
96.6% of Henry Schein shares are held by institutional investors. Comparatively, 87.2% of Cardinal Health shares are held by institutional investors. 1.1% of Henry Schein shares are held by company insiders. Comparatively, 0.2% of Cardinal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Cardinal Health had 5 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Cardinal Health and 6 mentions for Henry Schein. Cardinal Health's average media sentiment score of 1.61 beat Henry Schein's score of 1.26 indicating that Cardinal Health is being referred to more favorably in the news media.
Henry Schein has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
Henry Schein currently has a consensus target price of $81.73, suggesting a potential upside of 21.22%. Cardinal Health has a consensus target price of $107.57, suggesting a potential upside of 8.83%. Given Henry Schein's higher possible upside, equities analysts clearly believe Henry Schein is more favorable than Cardinal Health.
Summary
Henry Schein beats Cardinal Health on 10 of the 18 factors compared between the two stocks.
Get Henry Schein News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Henry Schein Competitors List
Related Companies and Tools
